Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus

 

Figure web 7: Trial sequential analysis for the trials exclusively dealing with glycaemic control on all-cause mortality.
Web7


Figure web 8: Trial sequential analysis for the trials exclusively dealing with glycaemic control on all-cause mortality including zero events.
Web8


Figure web 9: Trial sequential analysis for the trials exclusively dealing with glycaemic control on cardiovascular mortality.
Web9


Figure web 10: Funnel plot for cardiovascular mortality.
Webfig10


Figure web 11: Trial sequential analysis for all trials on non-fatal myocardial infarction.
Web11


Figure web 12: Trial sequential analysis for the trials exclusively dealing with glycaemic control on non-fatal myocardial infarction.
Web12

 

Figure web 13: Trial sequential analysis for all trials on amputation of lower extremity.
Web13

 

Figure web 14: Trial sequential analysis for the trials exclusively dealing with glycaemic control on amputation of lower extremity.
Web14

 

Figure web 15: Trial sequential analysis for all trials on microvascular complications as a composite outcome.
Web15

 

Figure web 16: Trial sequential analysis for the trials exclusively dealing with glycaemic control on microvascular complications as a composite outcome.
Web16

 

Figure web 17: Trial sequential analysis for all trials on nephropathy.
Web17

 

Figure web 18: Trial sequential analysis for the trials exclusively dealing with glycaemic control on nephropathy.
Web18

 

Figure web 19: Trial sequential analysis for all trials on retinopathy.
Web19

 

Figure web 20: Trial sequential analysis for the trials exclusively dealing with glycaemic control on retinopathy.
Webfig20

 

 

Figure web 21: Trial sequential analysis for all trials on retinal photocoagulation.
Web21

 

Figure web 22: Trial sequential analysis for all trials on serious adverse events.
Web22

 

Figure web 23: Trial sequential analysis for the trials exclusively dealing with glycaemic control on serious adverse events.
Web23

 

Figure web 24: Trial sequential analysis for all trials on mild hypoglycaemia.
Web24

 

Figure web 25: Trial sequential analysis for the trials exclusively dealing with glycaemic control on mild hypoglycaemia.
Web25

 

Figure web 26: Trial sequential analysis for all trials on severe hypoglycaemia.
Web26

 

Figure web 27: Trial sequential analysis for the trials exclusively dealing with glycaemic control on severe hypoglycaemia.
Web27